Peter J. Farago, MD.

Research Update

Methamphetamines and Opioid-Related Overdose Risk

April 1, 2023

Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers provide a detailed glimpse into the chaotic state of the illicit opioid supply and show that the potentially dangerous misconception that methamphetamines can be used as an opioid overdose reversal agent is widespread.

RESEARCH UPDATE

Thiamine Supplementation in Patients With Alcohol Use Disorder

January 30, 2023

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

We review an article that examines rates of thiamine supplementation for those with alcohol use disorder in the real world. Researchers wondered, how often is thiamine supplemented properly? The answer they found: not that often.

RESEARCH UPDATE

Sublocade vs SL Buprenorphine after Release from Jail

September 1, 2022

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

The period immediately following release from incarceration is associated with an elevated risk of overdose among those with opioid use disorder. In this randomized trial, researchers were able to show that long-acting injectable buprenorphine (Sublocade) is a feasible and effective treatment for this high-risk population.

Unintended Pregnancies in Opioid Use Disorder

March 1, 2022

Peter J. Farago, MD.

Peter J. Farago, MD. Dr. Farago has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Rates of unintended pregnancies are high among patients with opioid use disorder (OUD). In this study, researchers tested the efficacy of co-locating contraceptive services with treatment for OUD as well as the efficacy of providing financial incentives.